This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Exelixis, Protalix, Arena

"With Zytiga approved and MDV3100 and Alpharadin going to be filed for approval soon (and both available already under compassionate-use programs), Exelixis will have a tough time enrolling patients in Study 307. If we assume the trial starts now, I don't expect the company to have data until the first half of 2015 at the earliest, and that assumes a lightning-fast enrollment pace and an early halt for efficacy. How likely is it that the cabo trial can be halted early for efficacy? Not so much because cabo has yet to show any survival benefit to date. The drug is being studied at a new, lower dose and at every turn, it seems inferior to the competition. On pain, Alpharadin and Zytiga are better; on survival MDV3100, Provenge, Alpharadin and Zytiga win; and on quality of life, Alpharadin and Amgen's Xgeva win.

"I see two possible outcomes: Exelixis is forced to resize the trial, i.e. add more patients, which means more cost and more time; or Exelixis moves forward with the current trial size, setting up a very high-risk event that is more likely to fail."

Thank you, Bio-investor X.

Porter M. writes, "I want you on the record with a prediction for the Arena Pharmaceuticals panel. With all your negativity, you shouldn't be able to weasel out of being wrong when the panel votes to approve."

Not a problem. I predict Thursday's FDA advisory panel vote will be negative, meaning the recommendation will be for FDA to reject lorcaserin a second time. I don't have a guess on the actual vote count. I'm sure some of the experts will vote in lorcaserin's favor, just not enough. Recall, the first FDA advisory panel in September 2010 voted 9-5 against lorcaserin.

That's my prediction, on the record. If I'm wrong, you won't have to wait long for me acknowledge my error publicly. I will be live-blogging the lorcaserin FDA advisory panel, so please tune in. And don't worry, Arena will get fair treatment from me on the live blog.

Haley W. asks, "Isn't FDA adding many obesity experts to the Arena panel a good thing? Why would these people not want a new weight-loss drug to be approved?"

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ALXA $2.01 0.00%
ARNA $4.33 0.00%
EXEL $2.54 0.00%
MDVN $132.00 0.00%
PLX $1.77 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs